Study cohort
In total, 334 of >2000 individuals contacting specialized allergy centers because a self- and-or clinically suspected (Fig.1) immediate-type SARS-CoV-2 vaccine hypersensitivity were investigated (Fig. 2). The median age of this cohort was 49 years (19-91), and 291/334 were female (87.1%). Medical history data were available for 151/334 patients. The history of the patients included anaphylaxis in most cases to previous vaccination or drugs known or suspected to contain PEG or PS80. Few patients reported on immediate reactions after the use of cosmetics, were sensitized to multiple compounds or showed systemic reactions to contrast media (Table 1).